19805 N. CREEK PARKWAY, BOTHELL, WA
Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Announces Closing of Up To $13 Million Registered Direct Offering
Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Investor Presentation
Presents Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload